India Pharma · HCP Education Platforms · Competitive Intelligence 2026

What Indian Pharma
Has Actually Built
for Doctors

A verified comparative analysis of owned, doctor-facing HCP education platforms — every fact sourced, labelled, and attributable. No fabricated scores. No assumed data.

Platforms Assessed
4 Verified
Report Date
April 2026
Data Integrity
Sourced & Labelled
Includes
Gap Analysis
Scroll to explore
Data Key
Public Verifiable public source — press release, app store, independent case study
Company ◆ Disclosed by MediSamvad / Alkem project team — not independently published
N/D Not publicly disclosed
The Numbers

Registered Doctor Base —
What's Actually Known

The most important question in any platform comparison — and the one most companies refuse to answer publicly.

CiplaMed · Cipla
1,00,000+
Registered HCPs
✓ Google Play Store listing
Docflix · Mankind Pharma
—
Not disclosed publicly
No figure in any public source
DocVidya · Dr. Reddy's
—
Not disclosed publicly
No figure in any public source
MediSamvad · Alkem
1,80,000+
Registered doctors · as of Apr 2026
◆ Company-disclosed · MediSamvad project team

Note: CiplaMed's figure is from the Google Play app listing — total platform users (web + app) may be higher. MediSamvad's 1,80,000+ covers public launch (Dec 2024 press) through April 2026 — company-disclosed. Docflix and DRL have not published any HCP count in any public source.

Platform Profiles

What Each Platform
Actually Offers

Doctor-facing platforms only — where the HCP logs in directly. Cipla Assist (field force content delivery tool) is noted separately below as a different category.

Cipla
CiplaMed + CiplaMed Flix
India's oldest brand-owned HCP medical portal — unbiased, evidence-based content across 18–19 specialties, with a separate OTT-style CME app.
Pioneer · ~2014 onwards
Registered HCPs
1,00,000+
✓ Google Play listing
Specialties
18–19
✓ ciplamed.com + Play Store
Access
Web + iOS + Android
✓ App stores confirmed
Current Version
CiplaMed 2.0
✓ BioVoiceNews, Aug 2023
  • Public  eCME, guideline infographics, podcasts, expert videos, journal highlights, international conference coverage, patient education — Google Play listing
  • Public  Community section, Quick Reads, Events & Videos, Product Index, Conference Highlights, Guidelines — ciplamed.com navigation
  • Public  Content explicitly "unbiased" — goes beyond Cipla's own portfolio — ciplamed.com About page
  • Public  CiplaMed Flix (separate app): High-value CMEs by Healthcare Superstars in multiple languages, KOL content, premium articles, new launches, conference highlights with language selection, Content Interest Feature — Apple App Store
  • Public  Advanced analytics and automation referenced in v2.0 — BioVoiceNews, Aug 2023
  • N/D  Field force integration, CME accreditation body name, engagement metrics, prescription attribution
Verified Differentiator
Only platform with a two-product strategy publicly confirmed: CiplaMed for clinical reference, CiplaMed Flix for CME/KOL content. "Unbiased" content positioning (beyond Cipla's own portfolio) is explicitly stated. Largest publicly confirmed HCP base.
Mankind Pharma
Docflix
India's first OTT-format doctor education platform — scientific content produced like a show, not a slide deck. NID designers, scriptwriters, directors.
Launched May 2022
Registered HCPs
Not disclosed
No public figure
App Store Rating
4.8 / 5
✓ Apple App Store India (110 ratings)
Access
iOS + Android
✓ Both stores confirmed
CME Accreditation
Not offered
Absent from all sources
  • Public  OTT video platform — Medical Guidelines, Doctor Conferences, News, Expert Views sections — app store listings
  • Public  AI-driven personalisation confirmed live in app store descriptions — Google Play + Apple App Store
  • Public  Doctor avatars, peer chat, explore peer profiles — confirmed in app description
  • Public  Named shows: Science Simplified, Legend Inside the White Coat, Stitch in Time, Cardio Unflip, Digital for Doctors, Medico-legal Cases in India, Vantage Point — press coverage May 2022
  • Public  NID-trained designers, scriptwriters and directors produce content — IndianTelevision, MedDialogues, May 2022
  • N/D  HCP count, active users, field force integration, CME credits, engagement metrics
Verified Differentiator
Only platform where AI personalisation, peer chat, and doctor avatars are confirmed live features from public app store listings. Entertainment-grade production (NID, scriptwriters, directors) is a category-of-one. However: no CME, no published HCP count.
Dr. Reddy's Laboratories
DocVidya
A one-stop scientific learning platform — live webinars, CMEs, courses, expert talks, journal summaries, conference updates, and case-based forums. Multilingual including regional Indian languages. Has a dedicated section for rural India HCPs.
Built in <7 months · 2022
Registered HCPs
Not disclosed
No public figure
Tech Stack
Drupal 9 + Acquia
✓ QED42 + Drupal.org case study
Indian Languages
Tamil, Telugu, Bengali +
✓ docvidya.com About page
CRM
IQVIA OCE
✓ IQVIA + DRL press release, Sep 2022
  • Public  Live webinars, expert talks, CMEs, courses — docvidya.com About page
  • Public  Journal summaries, conference updates — docvidya.com About page
  • Public  Interactive case-based discussion forums — docvidya.com About page
  • Public  Multiple Indian languages — English, Tamil, Telugu, Bengali confirmed — docvidya.com About page
  • Public  VistaraEdge — dedicated section with curated learning resources specifically for healthcare practitioners in rural India — docvidya.com About page
  • Public  Specialties covered: gastroenterology, dermatology, cardiology, nephrology, pediatrics, urology + practice enhancement (finance, medico-legal, digital topics) — docvidya.com FAQ
  • Public  Login via Gmail, Facebook or Apple ID — docvidya.com FAQ
  • Public  Dual interface: text-based AND video-based with toggle — QED42 + Drupal.org case study
  • Public  Personalised weekly email recommendations + behaviour-based personalisation — QED42 case study
  • Public  IQVIA OCE deployed to entire India field force under multi-year agreement — IQVIA/DRL joint press release, Sep 2022
  • Public  Available at no cost to registered HCPs — docvidya.com
  • N/D  Registered HCP count, prescription attribution outcomes
Verified Differentiator
DocVidya is the only platform in this comparison that has publicly confirmed regional Indian language delivery (Tamil, Telugu, Bengali) for the Indian market — directly addressing the Tier 2-3 doctor. It is also the only platform with a dedicated section for rural India HCPs (VistaraEdge) — a gap every other platform ignores. Combined with IQVIA OCE across the entire India field force, DocVidya has the most complete publicly documented feature set of any platform here.
Alkem Laboratories
MediSamvad
Alkem's owned HCP education and engagement platform — publicly launched December 2024. The full feature set goes significantly beyond what the press covered.
Dec 2024 · Fastest Growing
Registered Doctors
1,80,000+
◆ Company-disclosed · Apr 2026
Platform Age
~18 months
✓ Dec 2024 press launch
Access
Web portal
✓ Launch coverage; no app announced
CME
Webinar portal
✓ Confirmed in launch press
  • Public  Research articles, case studies, clinical guidelines, global medical advancements — BioSpectrum, eHealth, BioVoiceNews, IndiaMedToday (Dec 2024)
  • Public  Dedicated web portal for CME webinars and peer community interaction — launch press coverage
  • Company ◆  Large-scale KOL-led webinars hosted on platform
  • Company ◆  RTMs (Round Table Meetings) conducted via platform
  • Company ◆  AdBoards (Advisory Boards) conducted via platform
  • Company ◆  Conference simulcasts — live streaming of major medical conferences to registered doctors
  • Company ◆  ISPs / International Symposia Programs — large-scale simulcasts
  • Company ◆  Medical association events hosted — specialty society doctor communities
  • Company ◆  AI Chatbot available to registered doctors on the platform
  • N/D  Field force integration (not publicly confirmed), multilingual support, mobile app, CME accreditation body name
Assessment
Fastest-growing platform in this comparison — 1,80,000+ registered doctors in ~18 months vs CiplaMed's 1,00,000+ over ~10 years. The feature depth — RTMs, AdBoards, simulcasts, ISPs, association events, chatbot — puts it firmly in the full-stack HCP engagement infrastructure category, not merely a knowledge portal. This is severely undercommunicated publicly.
⚑
Cipla Assist — A Different Category (Not Compared Here)
Cipla Assist is a field force content delivery tool — the Cipla field team accesses it, and content is delivered to mapped doctors via the rep. This is fundamentally different from the doctor-facing platforms above. It falls in the eDetailing / CLM (Closed Loop Marketing) category and is therefore not included in this comparison. CLIRNET has created content for Cipla Assist — this is not published in any public source.
Feature Matrix

Platform Features —
Side by Side

Every cell reflects what is publicly documented or company-disclosed. Nothing assumed.

Parameter ● CiplaMed ● Docflix ● DocVidya ● MediSamvad
Platform Fundamentals
Doctor Access Direct login — web + app Direct login — app Direct login — web Direct login — web portal
Launch Year ~2014; v2.0 Aug 2023 P May 2022 P 2022 P Dec 2024 P
Registered HCPs 1,00,000+ P Not disclosed Not disclosed 1,80,000+ ◆
Web Access ✓ P ✗ App only ✓ P ✓ P
iOS App ✓ CiplaMed + Flix P ✓ 4.8★ rating P Not confirmed ✗ Not announced
Android App ✓ P ✓ P Not confirmed ✗ Not announced
Content Formats
Clinical Articles / Guidelines ✓ Journal highlights, guidelines P ◐ Via shows ✓ Text content P ✓ Articles, case studies, guidelines P
Expert / KOL Videos ✓ P ✓ Core format P ✓ P ✓ KOL-led webinars ◆
Podcasts ✓ P Not confirmed Not confirmed Not confirmed
Infographics ✓ P Not confirmed Not confirmed Not confirmed
Conference Highlights ✓ International conferences P ✓ Conferences section P Not confirmed ✓ Live simulcasts ◆
Patient Education ✓ P Not confirmed Not confirmed Not confirmed
Live Engagement Formats
CME Webinars ✓ eCME confirmed P ✗ No CME announced ✓ Live webinars, CMEs, courses, expert talks confirmed P ✓ Dedicated webinar portal P
Large-Scale KOL Webinars Not specified Not specified Not specified ✓ ◆
RTMs (Round Table Meetings) ✗ ✗ ✗ ✓ ◆
AdBoards (Advisory Boards) ✗ ✗ ✗ ✓ ◆
Conference Simulcasts (Live) ✗ ✗ ✗ ✓ ◆
ISPs / International Symposia ✗ ✗ ✗ ✓ Large-scale simulcasts ◆
Association Events Hosted ✗ ✗ ✗ ✓ Specialty society events ◆
Technology & Personalisation
AI Personalisation ◐ Referenced in v2.0 P ✓ Confirmed live in app store P ✓ Behaviour-based + weekly email P Not confirmed publicly
AI Chatbot for Doctors ✗ ✗ ✗ ✓ Available to registered doctors ◆
Peer Interaction / Community ✓ Community section P ✓ Peer chat + avatars P Not specified ✓ Via webinar community P
Multilingual (India) ◐ CiplaMed Flix: multi-language CME P Not confirmed ✓ English, Tamil, Telugu, Bengali + more P Not confirmed publicly
Field Force Integration Not confirmed publicly Not confirmed publicly ✓ IQVIA OCE entire India FF P Not confirmed publicly
Named CME Accreditation Body ✗ eCME offered; body unnamed ✗ No CME at all ✓ API-certified P ◐ Webinar portal confirmed; body unnamed
First-Party Data Owned ✓ Owned platform ✓ Owned platform ✓ Owned + IQVIA layer ✓ Owned platform
Prescription Attribution Not published Not published IQVIA enables it; not claimed Not published

P Public — verifiable independent source  |  ◆ Company-disclosed — MediSamvad / Alkem project team  |  ✓ Yes   ◐ Partial   ✗ No   Blank = Not confirmed in any source

Industry Gaps

What the Entire Category
Hasn't Solved

Based on what is documented across all four platforms — and what is conspicuously absent from all of them.

Gap 01
No Platform Publishes Verified Engagement Data
CiplaMed is the only platform with a public HCP count. Docflix and DRL publish nothing. MediSamvad's 1.8L is company-disclosed, not independently published. There is no industry standard, no audit. Every pharma client making a platform decision is doing so blind.
Opportunity for MediSamvadPublishing the 1,80,000+ figure with methodology — even in a press release — makes it the most transparent platform in the market overnight.
Gap 02
Content → Prescription Attribution: Unproven Everywhere
No platform has publicly demonstrated: doctor engaged with content → field rep was informed → prescription behaviour shifted. DRL + IQVIA OCE has the infrastructure but hasn't published outcomes. This is the question every pharma commercial head wants answered — and every platform dodges it.
OpportunityEven a single division-level case study showing engagement-to-sales movement would be the most commercially compelling story in Indian pharma digital.
Gap 03
Regional Language — Solved by DocVidya, Ignored by Everyone Else
DocVidya is the only platform in this comparison that has confirmed regional Indian language delivery — Tamil, Telugu, Bengali and more — and has a dedicated section (VistaraEdge) for rural India HCPs. CiplaMed Flix mentions "multiple languages" for CME. MediSamvad and Docflix are English-only by all available evidence. With India's Tier 2-3 doctor being the majority of 1.3 million practising physicians, DocVidya has a meaningful head start on the most important accessibility dimension in Indian healthcare.
Opportunity for MediSamvadDocVidya has set the bar here. Any platform that matches regional language delivery moves from being a metro-focused portal to a genuinely national platform. This is now a competitive requirement, not just an opportunity.
Gap 04
CME Accreditation Transparency is Universally Poor
CiplaMed offers eCME but names no accrediting body. DRL names one API-certified programme. Docflix has no CME. MediSamvad has a CME portal but names no body. A doctor investing time on a platform for credits needs to know: which body, what structure, and is it recognized. None communicate this clearly.
OpportunityPublishing the accreditation body name and credit structure is a zero-cost upgrade that immediately improves doctor trust and time investment.
Gap 05 — The Strategic Gap
MediSamvad's Real Capabilities Are Almost Entirely Undercommunicated
The public record for MediSamvad — research articles, case studies, webinars — dramatically undersells what the platform actually does. RTMs, AdBoards, conference simulcasts, ISPs, association events, a chatbot, 1.8 lakh doctors — none of this is in the public domain. In any external comparison, MediSamvad appears as a basic knowledge portal launched in December 2024, when it is actually a full-scale HCP engagement infrastructure with a doctor base larger than CiplaMed's publicly stated figure. The gap between what MediSamvad is and what the market knows it is — is the biggest immediate opportunity.
Recommended ActionA single well-written press release or industry article covering the platform's actual feature set, 1.8L doctor milestone, event formats, and association partnerships would reposition MediSamvad from "new entrant" to "India's most comprehensive pharma HCP engagement platform." This story is waiting to be told.
MediSamvad · Competitive Position

Where MediSamvad Stands —
and the Way Forward

Based on combined public and company-disclosed data. Company-disclosed items marked ◆.

Established Leader
CiplaMed
Cipla
Verified HCPs
1,00,000+ (public)
Platform Age
~10+ years
Live Formats
eCME, webinars
Chatbot
Not confirmed
Key Edge
Scale + unbiased brand + dual app
Format Innovator
Docflix
Mankind Pharma
Verified HCPs
Not disclosed
Platform Age
3 years (2022)
Live Formats
None — no CME
Chatbot
Not confirmed
Key Edge
OTT format + AI + peer chat
Tech Leader
DocVidya
Dr. Reddy's Labs
Verified HCPs
Not disclosed
Platform Age
3 years (2022)
Live Formats
Webinars, CMEs, courses, forums ✓
Chatbot
Not confirmed
Key Edge
Global DXP + IQVIA FF loop
Full-Stack Engagement Platform
MediSamvad
Alkem Laboratories
Registered Doctors
1,80,000+ ◆
Platform Age
~18 months (fastest)
Live Formats
Webinars, RTMs, AdBoards, Simulcasts, ISPs ◆
Chatbot
✓ Confirmed ◆
Critical Gap
Story not told publicly
The Way Forward